EP1231920A1 - Solutions contenant de l'epinastine - Google Patents

Solutions contenant de l'epinastine

Info

Publication number
EP1231920A1
EP1231920A1 EP00972763A EP00972763A EP1231920A1 EP 1231920 A1 EP1231920 A1 EP 1231920A1 EP 00972763 A EP00972763 A EP 00972763A EP 00972763 A EP00972763 A EP 00972763A EP 1231920 A1 EP1231920 A1 EP 1231920A1
Authority
EP
European Patent Office
Prior art keywords
optionally
epinastine
conjunctiva
solution according
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP00972763A
Other languages
German (de)
English (en)
Other versions
EP1231920B1 (fr
Inventor
Volker Trach
Gerold Duschler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7928843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1231920(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to SI200030938T priority Critical patent/SI1231920T1/sl
Publication of EP1231920A1 publication Critical patent/EP1231920A1/fr
Application granted granted Critical
Publication of EP1231920B1 publication Critical patent/EP1231920B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01L—CYCLICALLY OPERATING VALVES FOR MACHINES OR ENGINES
    • F01L9/00—Valve-gear or valve arrangements actuated non-mechanically
    • F01L9/20—Valve-gear or valve arrangements actuated non-mechanically by electric means
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T137/00—Fluid handling
    • Y10T137/0318—Processes

Definitions

  • the invention relates to topically administrable aqueous solutions containing epinastine, optionally in the form of its racemate, its enantiomers, and optionally in the form of its pharmacologically acceptable acid addition salts.
  • Allergic reactions of the eye are understood to mean a number of differently defined clinical pictures.
  • Examples of ocular allergic reactions are: seasonal allergic conjunctivitis, perennial allergic conjunctivitis, giant cell conjunctivitis, vernal keratoconjunctivitis or atopic keratoconjunctivitis.
  • Seasonal allergic rhinitis and perennial allergic rhinitis may be mentioned as examples of allergic reactions of the nose (hereinafter nasal allergic reactions).
  • the immunological mechanism underlying ocular and nasal allergic reactions includes Inflammatory processes due to histamine.
  • the allergic reactions caused by the release of histamine occur at an early stage of the ocular and nasal allergic reactions mentioned at the beginning.
  • ocular and nasal allergic reactions can be caused by the release of further mast cell mediators as well as toxic eosinophilic granule proteins and enzymes.
  • LPR late-phase reaction
  • Conjunctiva conjunctiva of the eye
  • nasal mucosa the nasal mucosa
  • topically administrable aqueous solutions containing epinastine, optionally in the form of its racemate, its enantiomers and optionally in the form of its pharmacologically acceptable acid addition salts can be used to achieve the object on which the invention is based, since they can be used for the influx inhibit neutrophils and eosinophils in the tissues of the conjunctiva of the eye and the nasal mucosa, thereby reducing or preventing the occurrence of LPR and are accordingly characterized by a longer lasting duration of action.
  • the animals pretreated with the epinastine solution according to the invention (0.05-0.5%) had a significantly lower content of eosinophils in the conjunctiva.
  • the animals pretreated with the epinastine solution according to the invention had a significantly lower lymphocyte content in the conjunctiva (p ⁇ 0.01).
  • an approximately 35% inhibition of mast cell degranulation was determined (p ⁇ 0.01).
  • the invention consequently relates to topically administrable aqueous solutions containing epinastine, optionally in the form of its racemate, its enantiomers, and optionally in the form of its pharmacologically acceptable acid addition salts, in a concentration of 0.005 to 0.5, preferably 0.02 to 0.1, particularly preferably 0 , 03 to 0.07 mg / ml solution.
  • the above-mentioned topically administrable aqueous solutions containing epinastine hydrochloride are preferred.
  • Suitable aqueous solvents are physiologically compatible aqueous solvents, and physiologically compatible saline solutions are particularly preferred.
  • topically administrable solutions are preferably prepared which typically contain 0.005 to 0.5, preferably 0.02 to 0.1, particularly preferably 0.03 to 0.07 mg / ml epinastine, optionally in the form of its racemate, its enantiomers, and optionally in Contain form of its pharmacologically acceptable acid addition salts, as well as physiological saline solutions as the main carrier.
  • the pH of the solutions according to the invention should preferably be kept in the range from 6.5 to 7.2 using a suitable buffer system.
  • the preparations can also contain conventional, pharmaceutically acceptable auxiliaries, preservatives, stabilizers and / or penetration enhancers.
  • the preferred carrier that can be used in the solutions according to the invention is purified water and preferably a physiological saline solution.
  • viscosity agents such as polyvinyl alcohol, povidones, hydroxypropylmethylcellulose, poloxamers, carboxymethylcellulose, carbomer and hydroxyethylceilulose.
  • Preferred preservatives which can be used in the solutions according to the invention include, but are not limited to the subject matter of the invention, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercury acetate and phenylmercury nitrate.
  • the penetration enhancers can be, for example, surface-active agents, certain organic solvents such as dimethyl sulfoxide and other sulfoxides, dimethylacetamide and pyrrolidone, certain amides of heterocyclic amines, glycols such as propylene glycol, propylene carbonate, oleic acid, alkylamines and derivatives thereof various cationic, anionic, non-ionic and amphoteric surfactants and the like.
  • organic solvents such as dimethyl sulfoxide and other sulfoxides, dimethylacetamide and pyrrolidone
  • certain amides of heterocyclic amines such as propylene glycol, propylene carbonate, oleic acid, alkylamines and derivatives thereof various cationic, anionic, non-ionic and amphoteric surfactants and the like.
  • Tonic agents can be added as needed or appropriate. These include, without restricting the invention to the same, salts and in particular sodium chloride, potassium chloride, mannitol and glycerol or other suitable, physiologically compatible agents for adjusting the tonicity.
  • buffers and pH adjusting agents can be used as long as the preparation obtained is physiologically compatible.
  • Appropriate buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers.
  • physiologically acceptable antioxidants for use in the present invention include, but are not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, and butylated hydroxytoluene.
  • carrier components that can be incorporated into the solutions according to the invention are chelating agents.
  • the preferred chelating agent is disodium edetate (Na-EDTA), although other chelating agents can be used in place of or in conjunction with disodium edetate.
  • topically applicable aqueous solutions according to the invention can be applied either to the conjunctiva or to the nasal mucosa. Solutions for ophthalmic use are of equal importance to the present invention as solutions to be applied nasally.
  • the present invention also aims at the use of the above-mentioned topically applicable aqueous solutions for inhibiting the inflow of Neutrophils and eosinophils in the tissues of the conjunctiva of the eye or tissues of the nasal mucosa.
  • the present invention further aims at the use of epinastine, optionally in the form of its racemate, its enantiomers, and optionally in the form of its pharmacologically acceptable acid addition salts, for the preparation of the topically applicable aqueous solutions according to the invention for the treatment of disorders of the conjunctiva of the eye or the nasal mucosa inhibiting the influx of neutrophils and eosinophils into the tissues of the conjunctiva of the eye or the nasal mucosa has a therapeutic benefit in allergic reactions.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Detergent Compositions (AREA)

Abstract

L'invention concerne des solutions aqueuses d'application topique et contenant de l'épinastine, éventuellement sous la forme de son racémate, de son énantiomère ou encore de ses sels d'addition d'acide pharmacologiquement admissibles.
EP00972763A 1999-11-12 2000-10-14 Utilisation de l'epinastine pour le traitment de la rhinite/conjonctivite allergique Expired - Lifetime EP1231920B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI200030938T SI1231920T1 (sl) 1999-11-12 2000-10-14 Uporaba epinastina za zdravljenje alergijskega renitisa/konjuktivitisa

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19954516 1999-11-12
DE19954516A DE19954516A1 (de) 1999-11-12 1999-11-12 Epinastin-haltige Lösungen
PCT/EP2000/010122 WO2001035962A1 (fr) 1999-11-12 2000-10-14 Solutions contenant de l'epinastine

Publications (2)

Publication Number Publication Date
EP1231920A1 true EP1231920A1 (fr) 2002-08-21
EP1231920B1 EP1231920B1 (fr) 2007-02-07

Family

ID=7928843

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00972763A Expired - Lifetime EP1231920B1 (fr) 1999-11-12 2000-10-14 Utilisation de l'epinastine pour le traitment de la rhinite/conjonctivite allergique

Country Status (40)

Country Link
US (6) US20030050303A1 (fr)
EP (1) EP1231920B1 (fr)
JP (1) JP2003514021A (fr)
KR (1) KR100758842B1 (fr)
CN (1) CN1292752C (fr)
AR (1) AR026424A1 (fr)
AT (1) ATE353218T1 (fr)
AU (2) AU784017B2 (fr)
BG (1) BG65775B1 (fr)
BR (1) BR0015477A (fr)
CA (1) CA2391076C (fr)
CO (1) CO5251448A1 (fr)
CY (1) CY1106375T1 (fr)
CZ (1) CZ302483B6 (fr)
DE (2) DE19954516A1 (fr)
DK (1) DK1231920T3 (fr)
EA (1) EA006937B1 (fr)
EE (1) EE05395B1 (fr)
ES (1) ES2281359T3 (fr)
HK (1) HK1052303B (fr)
HR (1) HRP20020404B1 (fr)
HU (1) HU229502B1 (fr)
IL (2) IL149501A0 (fr)
ME (1) MEP36708A (fr)
MX (1) MXPA02004556A (fr)
MY (1) MY130441A (fr)
NO (1) NO329417B1 (fr)
NZ (1) NZ519425A (fr)
PE (1) PE20010826A1 (fr)
PL (1) PL198879B1 (fr)
PT (1) PT1231920E (fr)
RS (1) RS50173B (fr)
SA (1) SA01210658B1 (fr)
SI (1) SI1231920T1 (fr)
SK (1) SK287343B6 (fr)
TR (1) TR200201270T2 (fr)
TW (1) TWI225401B (fr)
UA (1) UA74563C2 (fr)
WO (1) WO2001035962A1 (fr)
ZA (1) ZA200203683B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791154B2 (en) 2011-05-19 2014-07-29 Alcon Research, Ltd. High concentration olopatadine ophthalmic composition

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
WO2004014353A1 (fr) * 2002-08-02 2004-02-19 Boehringer Ingelheim International Gmbh Formulations pharmaceutiques a combinaisons d'epinastine, de pseudoephedrine et de methylephedrine
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
EP1468696A1 (fr) * 2003-04-17 2004-10-20 Boehringer Ingelheim International GmbH Combinaisons d'épinastine et d'agents antiphlogistiques comme nouvelles compositions pharmaceutiques pour le traitement de maladies de la peau
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
CN101217948A (zh) * 2005-07-08 2008-07-09 千寿制药株式会社 包含依匹那丁的透皮吸收眼科制剂
US20080194544A1 (en) * 2007-02-08 2008-08-14 Ramesh Krishnamoorthy Aqueous formulations of epinastine for treating allergic rhinitis
US7378082B1 (en) 2007-11-05 2008-05-27 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects
WO2008098122A2 (fr) * 2007-02-08 2008-08-14 Inspire Pharmaceuticals, Inc. Procédé de traitement de rhinite allergique sans effets indésirables
US20120203161A1 (en) * 2009-08-12 2012-08-09 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use
EP2630952A1 (fr) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Dispersions d'huile à conservation indépendante comprénant de l'acide borique
BR112015014367B1 (pt) * 2012-12-19 2022-11-22 Novartis Ag Composição inibidora de lfa-1, método para estabilizar a dita composição e uso da mesma para tratar uma doença ocular
CN104491876A (zh) * 2014-12-23 2015-04-08 中国药科大学 含玻璃酸钠的依匹斯汀滴眼液及其制备方法
ITUB20153950A1 (it) * 2015-09-28 2017-03-28 Tred Srl Dispositivo nasale in grado di attivare il riflesso rino-palatale per l'igienizzazione rinofaringea
JP6134853B1 (ja) * 2016-10-28 2017-05-24 参天製薬株式会社 エピナスチン含有点眼液
JP6635974B2 (ja) * 2017-04-24 2020-01-29 参天製薬株式会社 エピナスチン含有点眼液
WO2018203424A1 (fr) * 2017-05-01 2018-11-08 参天製薬株式会社 Collyre
JP2019108320A (ja) * 2018-10-31 2019-07-04 参天製薬株式会社 ソフトコンタクトレンズの変質を抑制する眼科用組成物
JP7599838B2 (ja) * 2019-04-10 2024-12-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物
JP6736752B2 (ja) * 2019-12-17 2020-08-05 参天製薬株式会社 エピナスチン含有点眼液
JP7118579B1 (ja) 2020-04-16 2022-08-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性組成物
JP6963651B2 (ja) 2020-04-16 2021-11-10 参天製薬株式会社 エピナスチン又はその塩を含有する水性組成物
JP2020169213A (ja) * 2020-07-15 2020-10-15 参天製薬株式会社 エピナスチン含有点眼液
JP7114668B2 (ja) * 2020-10-08 2022-08-08 参天製薬株式会社 エピナスチン又はその塩を含有する花粉破裂抑制剤
CN115448927A (zh) * 2022-10-20 2022-12-09 重庆瑞泊莱医药科技有限公司 一种氢溴酸依匹斯汀晶型ii及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US151541A (en) * 1874-06-02 Improvement in hay-loaders
US215396A (en) * 1879-05-13 Improvement in loom-temples
US228359A (en) * 1880-06-01 jones
US181478A (en) * 1876-08-22 Improvement in water-wheels
US104017A (en) * 1870-06-07 Improvement in embroidering attachment for sewing-machines
US8632A (en) * 1852-01-06 George hess
US203021A (en) * 1878-04-30 Improvement in side-bar wagons
DE3008944A1 (de) * 1980-03-08 1981-09-24 C.H. Boehringer Sohn, 6507 Ingelheim Dibenzimidazoazepine, ihre herstellung und verwendung
DE4102148A1 (de) * 1991-01-25 1992-07-30 Boehringer Ingelheim Kg Verfahren zur herstellung von 3-amino-9,13b-dihydro-1h-dibenz-(c,f)imidazol(1,5-a)azepin-hydrochlorid
US5668133A (en) * 1992-12-09 1997-09-16 Alcon Laboratories, Inc. Ophthalmic compositions comprising emedastine and methods for their use
UA62917C2 (en) * 1995-06-27 2004-01-15 Berinher Inhelheim Kg Medicinal composition for generating propellant-free aerosols
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
US6201011B1 (en) * 1996-08-30 2001-03-13 Kyoto Pharmaceutical Industries, Ltd. Therapeutic agent for allergic dermatitis
US20030215396A1 (en) * 1999-09-15 2003-11-20 Boehringer Ingelheim Pharma Kg Method for the production of propellant gas-free aerosols from aqueous medicament preparations
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
EP0903151A1 (fr) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Utilisation de combinations comprenant des antihistamines non sédatives et des agonistes alpha-adrenergiques pour le traitement topical du rhinitis/conjunctivitis et des symptomes du rhume et de la grippe
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
MXPA02005007A (es) * 1999-11-18 2004-08-12 Alcon Inc Uso de un antagonista h1 y un esteroide inocuo para tratar condiciones oculares.
DE19958460A1 (de) * 1999-12-03 2001-06-07 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Epinastine-Hydrochlorid in der hochschmelzenden Kristallmodifikation
FR2803520B1 (fr) * 2000-01-12 2002-09-20 Ceva Sante Animale Procede pour augmenter la production d'oeufs et consolider la coquille des oeufs chez les volailles
US20020094345A1 (en) * 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
DE10119718A1 (de) * 2001-04-21 2002-10-31 Boehringer Ingelheim Pharma Verfahren zur kontinuierlichen Herstellung inhalierfähiger Arzneistoffe, Vorrichtung zur Durchführung des Verfahrens und nach diesem Verfahren hergestellter Arzneistoff
AU2002305780A1 (en) * 2001-05-29 2002-12-09 Transchip, Inc. Patent application cmos imager for cellular applications and methods of using such
US20030104017A1 (en) * 2001-10-26 2003-06-05 Boehringer Ingelheim International Gmbh Epinastine formulation for oral administration
EP1350512A1 (fr) * 2002-04-03 2003-10-08 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Formulation d'une combinaison d'epinastine, de belladone et de pseudoephedrine
US6863848B2 (en) * 2002-08-30 2005-03-08 Signet Armorlite, Inc. Methods for preparing composite photochromic ophthalmic lenses
JP2007145316A (ja) * 2005-10-27 2007-06-14 Nissan Motor Co Ltd 遮光装置とサンバイザーとサンルーフユニット

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0135962A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791154B2 (en) 2011-05-19 2014-07-29 Alcon Research, Ltd. High concentration olopatadine ophthalmic composition
US9533053B2 (en) 2011-05-19 2017-01-03 Alcon Research, Ltd. High concentration olopatadine ophthalmic composition

Also Published As

Publication number Publication date
PL198879B1 (pl) 2008-07-31
NZ519425A (en) 2004-04-30
HUP0203773A3 (en) 2005-01-28
ATE353218T1 (de) 2007-02-15
EA200200492A1 (ru) 2002-10-31
HRP20020404B1 (hr) 2007-08-31
PE20010826A1 (es) 2001-08-20
UA74563C2 (uk) 2006-01-16
EE200200246A (et) 2003-06-16
KR100758842B1 (ko) 2007-09-19
RS50173B (sr) 2009-05-06
EP1231920B1 (fr) 2007-02-07
BG65775B1 (bg) 2009-11-30
NO20022201D0 (no) 2002-05-08
TWI225401B (en) 2004-12-21
US20070197503A1 (en) 2007-08-23
CO5251448A1 (es) 2003-02-28
TR200201270T2 (tr) 2002-12-23
SK287343B6 (sk) 2010-07-07
EE05395B1 (et) 2011-04-15
US20080009476A1 (en) 2008-01-10
BR0015477A (pt) 2002-06-25
BG106681A (en) 2002-12-29
JP2003514021A (ja) 2003-04-15
IL149501A0 (en) 2002-11-10
US20030050303A1 (en) 2003-03-13
PL364028A1 (en) 2004-11-29
CZ20021956A3 (cs) 2002-08-14
HRP20020404A2 (en) 2004-08-31
HUP0203773A2 (hu) 2003-03-28
DE50014041D1 (de) 2007-03-22
ES2281359T3 (es) 2007-10-01
US20070185082A1 (en) 2007-08-09
EA006937B1 (ru) 2006-06-30
ZA200203683B (en) 2003-09-03
MY130441A (en) 2007-06-29
NO329417B1 (no) 2010-10-18
DK1231920T3 (da) 2007-04-10
CY1106375T1 (el) 2011-10-12
YU33602A (sh) 2005-03-15
DE19954516A1 (de) 2001-05-17
HK1052303B (zh) 2007-04-13
MXPA02004556A (es) 2004-09-10
KR20020050273A (ko) 2002-06-26
SK8302002A3 (en) 2002-09-10
CA2391076A1 (fr) 2001-05-25
AR026424A1 (es) 2003-02-12
US7429602B2 (en) 2008-09-30
AU784017B2 (en) 2006-01-12
AU2006201541A1 (en) 2006-05-11
AU1138101A (en) 2001-05-30
HK1052303A1 (en) 2003-09-11
IL149501A (en) 2012-04-30
HU229502B1 (en) 2014-01-28
SI1231920T1 (sl) 2007-06-30
CN1390129A (zh) 2003-01-08
NO20022201L (no) 2002-05-08
US20050288274A1 (en) 2005-12-29
MEP36708A (en) 2011-02-10
PT1231920E (pt) 2007-03-30
WO2001035962A1 (fr) 2001-05-25
CZ302483B6 (cs) 2011-06-08
CA2391076C (fr) 2008-06-17
CN1292752C (zh) 2007-01-03
SA01210658B1 (ar) 2006-11-05
US20090239842A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
EP1231920B1 (fr) Utilisation de l'epinastine pour le traitment de la rhinite/conjonctivite allergique
DE68913650T2 (de) Antiglaukoma-zubereitungen, die kombinationen von alpha-2 agonisten und beta-blocker enthalten.
DE69630325T3 (de) Nervenschutzende für Auge von Säugern unter Anwendung von Kaliumkanalblockern
DE69900207T2 (de) Verwendung von 11-(3-dimethylaminopropyliden)-6,11-dihydrodibenz[b,e]oxepin-2-essigsäure und deren pharmazeutisch annehmbaren salzen zur herstellung eines medikaments zur behandlung nicht-allergisch-bedingten augenentzündungen und zur prevention der okularen neovaskularisation
US6649602B1 (en) Use of an H1 antagonist and a safe steroid to treat eye conditions
EP2002841A1 (fr) Composition ophtalmique comprenant de la gomme de xanthane et du glucose
DE19729879A1 (de) Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
DE60132325T2 (de) Ophthalmische lösung
DE69426062T2 (de) Zusammensetzungen von ergolinderivaten zur behandlung des glaukoms
DE69819900T2 (de) Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil
DE69326840T2 (de) Ophtalmische Zusammensetzungen enthaltenden Emedastine und ihre Verwendungzur Behandlung von allergischer Konjunktivitis
DE2330338A1 (de) Okular-hypotensives mittel
CA2165999A1 (fr) Composition pharmaceutique pour administration oculaire topique dans le traitement de la conjonctivite d'origine allergene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020612

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 20020612;LV PAYMENT 20020612;RO PAYMENT 20020612;SI PAYMENT 20020612

17Q First examination report despatched

Effective date: 20030331

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/14 20060101ALI20060206BHEP

Ipc: A61K 31/55 20060101AFI20060206BHEP

Ipc: A61K 9/08 20060101ALI20060206BHEP

Ipc: A61P 11/02 20060101ALI20060206BHEP

Ipc: A61P 27/02 20060101ALI20060206BHEP

RTI1 Title (correction)

Free format text: USE OF EPINASTIN FOR THE TREATMENT OF ALLERGIC RHINITIS/CONJUNCTIVITIS

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: LT LV RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REF Corresponds to:

Ref document number: 50014041

Country of ref document: DE

Date of ref document: 20070322

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20070313

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20070400777

Country of ref document: GR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20070503

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2281359

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20071108

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20190919

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20191021

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20191022

Year of fee payment: 20

Ref country code: MC

Payment date: 20191014

Year of fee payment: 20

Ref country code: SE

Payment date: 20191021

Year of fee payment: 20

Ref country code: CY

Payment date: 20191011

Year of fee payment: 20

Ref country code: FI

Payment date: 20191022

Year of fee payment: 20

Ref country code: NL

Payment date: 20191021

Year of fee payment: 20

Ref country code: DE

Payment date: 20191021

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20191028

Year of fee payment: 20

Ref country code: ES

Payment date: 20191122

Year of fee payment: 20

Ref country code: GR

Payment date: 20191022

Year of fee payment: 20

Ref country code: DK

Payment date: 20191023

Year of fee payment: 20

Ref country code: IT

Payment date: 20191028

Year of fee payment: 20

Ref country code: BE

Payment date: 20191021

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20191021

Year of fee payment: 20

Ref country code: AT

Payment date: 20191022

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20191021

Year of fee payment: 20

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20201013

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20201014

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20201014

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20201013

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 353218

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201014

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20201013

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20201023

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20201014

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20201015